Villani S, et al. – Experts introduced a multiplex array analysis of circulating cytokines and chemokines in natalizumab–treated patients with multiple sclerosis. This study did not find polyomavirus JC (JCPyV)–related progressive multifocal leukoencephalopathy (PML) in any patient. Therefore, natalizumab had a marginal impact on the systemic immunity.